It's a scary thought: why do some children battling myocarditis, an inflammation of the heart muscle, end up with heart failure, a condition that can be fatal? A groundbreaking study sheds light on this, suggesting a hidden culprit: genetic variants. But here's where it gets interesting...
The research reveals that a specific genetic variant significantly increases the risk of heart failure in children with myocarditis. Specifically, 34.4% of children who developed dilated cardiomyopathy (a condition where the heart's main pumping chamber stretches and thins, potentially leading to heart failure) after myocarditis possessed this variant. Compare that to a mere 6.3% in a control group without cardiomyopathy, and the difference is stark. This disparity is statistically significant, highlighting the crucial role of genetics.
Myocarditis, while rare, is a serious condition and has been identified as a leading cause of sudden death in individuals under 20 years old. Dilated cardiomyopathy, in particular, is a dangerous complication, as the heart struggles to pump enough blood and oxygen throughout the body.
This research suggests that genetic testing could be a game-changer for children diagnosed with myocarditis and cardiomyopathy. According to Steven E. Lipshultz, the study's corresponding author and a professor at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, "Very few doctors do genetic testing for cardiomyopathy-causing pathologic gene variants when a child comes in with new onset heart failure."
The study examined 32 children with dilated cardiomyopathy and myocarditis, comparing them to children with myocarditis who didn't develop cardiomyopathy, and a group of healthy controls. The children with cardiomyopathy were part of the Pediatric Cardiomyopathy Registry (PCMR), a network of U.S. and Canadian centers founded and led by Lipshultz.
Lipshultz notes that the common belief has been that specific infections lead to myocarditis and heart failure. However, he points out that infants typically experience about 7 infections in their first year of life, yet only a small fraction develop myocarditis and heart failure or experience sudden death.
This led Lipshultz to suspect an additional factor was at play, particularly when children with common viruses and upper respiratory symptoms suddenly develop severe myocarditis, sometimes with tragic outcomes. He and his colleagues previously found that some families had genetic mutations that weakened the immune systems of these children, making them vulnerable to common viruses.
Lipshultz theorized that if a child had gene mutations for cardiomyopathy, it would reduce their cardiac reserve, which is the heart's ability to handle increased physical demands. He and his colleagues call this the “double hit.” The first “hit” is the pathological cardiomyopathy mutation, increasing the risk of cardiomyopathy and heart failure. The second “hit” is an infection that affects the heart muscle cells, leading to myocarditis.
"In the new study, we found that a statistically significantly greater proportion of children coming into children’s hospitals and intensive care units for heart failure and new onset myocarditis had pathological cardiomyopathy gene mutations,” says Lipshultz.
These mutations, he explains, reduce cardiac reserve and increase the likelihood of heart failure compared to those with myocarditis without heart failure. Therefore, identifying these gene mutations is critical upon diagnosis.
Furthermore, these mutations elevate the risk of recurrent myocarditis episodes and sudden cardiac death, making these children potential candidates for implantable cardiac defibrillators. The message for clinicians is clear: if you don't look for pathologic genetic mutations, you might miss identifying a patient at higher risk of sudden death. Lipshultz emphasizes, "But if you do look and you find concerning risk factors, you should act.”
The research is published in Circulation Heart Failure. All genetics studies related to this research were led by Stephanie Ware, chair of medical and molecular genetics at Indiana University School of Medicine.
Co-authors on the study included researchers from various institutions, including Washington University School of Medicine, Indiana University School of Medicine, Cincinnati Children’s Hospital, and others. The study was funded by the National Heart, Lung and Blood Institute PCMR, the Pediatric Cardiomyopathy Genes study, the Children’s Cardiomyopathy Foundation, the Kyle John Rymiszewski Foundation, and Sofia’s Hope Inc.
So, what do you think? Does this genetic connection change how we should approach treating children with myocarditis? Could widespread genetic testing be the key to preventing tragic outcomes? Share your thoughts in the comments below!
